Elevate Your Investing Strategy:
- Take advantage of TipRanks Premium at 50% off! Unlock powerful investing tools, advanced data, and expert analyst insights to help you invest with confidence.
The latest announcement is out from Alcidion Group Limited ( (AU:ALC) ).
Alcidion Group Limited, a leader in healthcare technology solutions, announced significant achievements at its 2025 Annual General Meeting. The company reported a record-setting fiscal year with total revenue of $40.8 million, a 10% increase from the previous year, and secured $73.8 million in new contracts. Notably, Alcidion’s Miya Precision platform continues to gain traction, highlighted by a landmark $39 million contract with North Cumbria NHS Trust. The company’s financial health is robust, with no debt and a cash reserve of $17.7 million, positioning it well for further growth and innovation in the healthcare sector.
The most recent analyst rating on (AU:ALC) stock is a Buy with a A$0.13 price target. To see the full list of analyst forecasts on Alcidion Group Limited stock, see the AU:ALC Stock Forecast page.
More about Alcidion Group Limited
Alcidion Group Limited is a company focused on transforming healthcare through proactive, smart, and intuitive technology solutions. It offers a set of software products and technical services, with its flagship product being Miya Precision. This platform provides real-time clinical decision support, interoperability, and data visualization, aiming to improve patient care efficiency and quality. Alcidion operates globally, serving over 400 hospitals and 87 healthcare organizations, with a strong presence in the UK, Australia, and New Zealand.
Average Trading Volume: 907,037
Technical Sentiment Signal: Hold
Current Market Cap: A$124.9M
See more insights into ALC stock on TipRanks’ Stock Analysis page.